Zydus Life on Saturday, March 23, said that it has received tentative approval from the USFDA to market Letermovir tablets, 240 mg and 480 mg ... and marketing of Edaravone Injection in the dose 30 mg ...
Some results have been hidden because they may be inaccessible to you